Since Wallis et al presented 2 independent rates for populations using either infliximab (IFX) or etanercept (ETN), with results quite different from each other, each incidence was considered as the sole factor in the calculation.[20] The incidence rate of histoplasmosis was 33.52 cases per 100,000 patients treated with TNF-α inhibitors (95% CI 12.28–91.46). Here, TNF is linked to histoplasmosis.